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ABSTRACT
The androgen receptor is a key transcription factor contributing to the 
development of all stages of prostate cancer (PCa). In addition, other transcription 
factors have been associated with poor prognosis in PCa, amongst which c-Myc (MYC) 
is a well-established oncogene in many other cancers. We have previously reported 
that the AR promotes glycolysis and anabolic metabolism; many of these metabolic 
pathways are also MYC-regulated in other cancers. In this study, we report that in 
PCa cells de novo purine biosynthesis and the subsequent conversion to XMP is tightly 
regulated by MYC and independent of AR activity. We characterized two enzymes, 
PAICS and IMPDH2, within the pathway as PCa biomarkers in tissue samples and 
report increased efficacy of established anti-androgens in combination with a clinically 
approved IMPDH inhibitor, mycophenolic acid (MPA). Treatment with MPA led to a 
significant reduction in cellular guanosine triphosphate (GTP) levels accompanied by 
nucleolar stress and p53 stabilization. In conclusion, targeting purine biosynthesis 
provides an opportunity to perturb PCa metabolism and enhance tumour suppressive 
stress responses.
INTRODUCTION
Prostate cancer (PCa) is the most common cancer 
in men in the United States and Europe [1]. Decades of 
research have shown that the androgen receptor (AR), 
a steroid hormone-activated transcription factor is a 
major driver of disease initiation and progression. Thus, 
androgen-deprivation therapy strives to perturb AR 
activity and complements conventional cancer therapies, 
such as radical prostatectomy, radio- or chemotherapy. 
However, progression to castration-resistant prostate 
cancer (CRPC) occurs frequently and is ultimately fatal 
[2]. Interestingly, most CRPC cases still express AR 
and display an active AR network [3, 4]. Amplifications 
or mutations in the AR gene are thought to facilitate the 
development of CRPC, presumably by rendering the 
AR sensitive to other ligands or lower concentrations of 
androgens [5, 6].
Naturally, the AR and its target genes have been at 
the centre of extensive research to explore better detection 
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and treatment options. Recently, unbiased whole-genome 
approaches in PCa cell lines have defined the AR as a 
master regulator of cell cycle genes and core metabolic 
networks resulting in increased anabolic metabolism [7].
Besides the AR, genes for other transcription factors, 
such as c-Myc (MYC), are known to be overexpressed 
or amplified in PCa and to contribute to disease initiation 
and progression [8–10]. MYC acts as a heterodimeric 
transcription factor in complex with its partner protein 
MAX [11]. The assembled complex binds to consensus 
binding motifs called E-boxes and regulates the expression 
of its target genes [12]. Interestingly and resembling core 
AR functions, extensive work in various other cell line 
models discovered genes involved in cell cycle, ribosome 
biogenesis and metabolism to be among MYC’s targets, 
highlighting its impact on proliferation and biomass 
accumulation [13–15].
Intriguingly, while transcriptional networks for 
MYC have been thoroughly and unbiasedly defined in 
other cell line models [16], the work performed in PCa 
remained scarce until lately. Recent work performed in 
PCa models suggests similar roles for MYC in ribosome 
biogenesis and amino acid metabolism [17, 18]. The 
contribution of MYC to disease progression, however, 
remains poorly understood.
In this study, we combine in vitro and clinical 
expression data to determine clinically relevant MYC-
regulated transcriptional networks and assess their 
therapeutic potential. We show that MYC tightly regulates 
the expression of genes in the de novo purine biosynthesis 
pathway. Furthermore, we report for the first time that 
inhibition of the rate-limiting enzyme for guanine 
nucleotide biosynthesis, IMPDH2, promotes nucleolar 
stress and enhances responses to anti-androgens and 
androgen synthesis inhibitors.
RESULTS
MYC regulates the expression of a core set 
of genes and pathways in vitro and is highly 
correlated with their expression in vivo
To decipher gene networks regulated by MYC in 
PCa, we used a stably transfected MYC-overexpressing 
LNCaP cell line model recently published and further 
referred to as LNCaP MYC [19]. Upon stimulation with 
Doxycycline, MYC protein levels rapidly increased to 
approximately 4-fold and remained stable for at least 12 h. 
At the transcript level Doxycycline induced maximally an 
8-fold increase at 24 hours (Figure S1A and S1B).
Androgen treatment of LNCaP reduced MYC 
expression levels as previously reported (Figure S1F 
and S1G) [20]. Consequently, to determine the MYC-
regulated transcriptome, we cultured LNCaP MYC 
cells in the absence of androgens prior to stimulation 
with Doxycycline for 5 h and 12 h. These conditions 
were chosen to capture primarily direct MYC-mediated 
effects on transcription whilst limiting AR activation. 
Using an unbiased Gene Set Enrichment Analysis 
(GSEA) approach, we found SCHUHMACHER_MYC_
TARGETS_UP to be the top upregulated gene set at 12 h 
amongst the entire c2: curated gene sets (Figure S1C and 
Table S3 for Top 10 up- and downregulated gene sets). 
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analysis using a web-based tool [21] (http://genecodis.
cnb.csic.es/) on the 266 genes significantly upregulated 
by MYC overexpression at both time points (Table S1) 
revealed pathway enrichment for ribosome biogenesis, 
amino acid metabolism and nucleotide metabolism 
(Figure 1A).
In parallel, to identify MYC co-expressed genes in 
clinical samples we downloaded clinical expression data 
and applied a Pearson correlation coefficient with a 1% 
tolerance seeded on MYC [22]. The dataset consisted 
of metastatic PCa cases and primary tumours for which 
there was evidence of biochemical relapse (BCR). 
This approach identified a total of 264 genes that were 
tightly linked to MYC expression levels in those patients 
(Figure 1B and Table S2). We then applied this gene set 
to Genecodis and observed a strikingly similar pathway 
enrichment to the one derived from MYC-dependent 
genes in our cell line dataset (Figure 1B), indicating that 
MYC-dependent genes are highly conserved between 
tissue and cell lines.
Next to ribosome biogenesis, for which a role 
of MYC has previously been reported [17], purine 
metabolism and especially the de novo purine biosynthesis 
was the most significantly enriched pathway both 
in vitro and in vivo (Figure 1A/B). The most consistently 
overexpressed genes within this pathway across 16 clinical 
expression array datasets were PAICS and IMPDH2, 
as determined by the Oncomine microarray database 
(Figure S1D). PAICS correlates with MYC expression 
in the Taylor dataset with an R2 of 0.625 and IMPDH2 
with an R2 of 0.680 (Figure S1E). These are even tighter 
correlations than the one observed for the AR and its well-
established target gene KLK3 (R2 = 0.352) and similar to 
the previously reported correlation between ERG and its 
strong target gene TDRD1 (R2 = 0.734) (Figure S1E) [24].
The expression of genes involved in purine 
metabolism in prostate cancer cells is controlled 
by MYC
Subsequently, we moved on to PCa cell lines and 
initially explored whether enzymes in this pathway were 
androgen-dependent. We treated hormone-deprived 
LNCaP and VCaP cells with the synthetic androgen 
R1881 (1 nM), which activates the AR. Strikingly, no 
significant increase in transcript levels of any of the genes 
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in the pathway could be seen after 5 h or 12 h treatment 
(Figure S1F). We also blotted for two genes in the 
pathway, PAICS and IMPDH2, and observed no significant 
changes on a time course from 6–72 hours (Figure S1G). 
By contrast, KLK3, an established AR target gene, was 
significantly induced by the treatment, both at the protein 
and mRNA levels (Figure S1F and S1G).
Next we assessed the role of MYC in the 
transcriptional regulation of these enzymes. An obligate 
dependency on MYC would imply that expression levels 
of target genes would mirror changes in MYC levels, both 
upon overexpression and knockdown. First, we used the 
abovementioned LNCaP MYC overexpressing model to 
validate our microarray predictions and assessed transcript 
changes after 5 h and 12 h of MYC overexpression. 
As positive controls, we selected two highly ranked 
genes, NOP16 and DKC1, which are also previously 
reported MYC target genes [25, 26], and two top up- and 
downregulated genes from our microarrays (RRP12 and 
GEMIN4 and ACPP and GPER, respectively). Strikingly, 
with the exception of ADSSL1 and IMPDH1,  all de novo 
purine biosynthesis and IMP-converting enzymes showed 
a significant (P < 0.05) increase in their mRNA levels 
upon MYC overexpression of a similar magnitude to the 
positive controls (Figure 1C). At the protein level, no 
significant changes could be observed at the 5 h or 12 h 
timepoints (data not shown). However, the appropriate 
timepoints to assess protein changes relative to transcript 
changes are challenging to predict since other factors, such 
as the availability of metabolites or the conformation and 
stability of the enzymes in response to substrate binding, 
can affect the protein levels of these enzymes, too.
MYC target genes have previously been reported to 
be responsive to MYC knockdown [17]. Consequently, 
we used siRNA against MYC and achieved a knockdown 
of about 70% in LNCaP cells and of 50% in VCaP cells 
at the mRNA level and about 70% at the protein level in 
both lines (Figure 1D/E and S1H). This led to a significant 
(P < 0.05) reduction of the mRNA levels of PPAT, GART, 
PFAS, PAICS, ADSL and IMPDH2 in both cell lines with 
the established MYC-target DKC1 serving as a positive 
control (Figure 1D).
Using Western blotting, we also observed a strong 
and reproducible reduction (30–40%) in the protein levels 
of PAICS and IMPDH2 (Figure 1E and S1H).
The tight co-expression of these enzymes with 
changes in MYC expression implies that these genes 
may be directly regulated by MYC. It has recently been 
reported that MYC binds preferentially to the proximal 
promoters of target genes and a number of MYC ChIP-
seq datasets are available through the ENCODE initiative 
for cell lines, although strikingly not PCa cell lines [27]. 
We identified overlapping MYC consensus binding 
sites in a minimum of three cancer cell lines lying at the 
transcription start sites (TSS) of every gene in the pathway 
(Figure S2). To determine whether these were indeed 
sites of MYC recruitment in PCa cell lines (LNCaP and 
VCaP), we designed primers against these consensus sites 
(Figure S2A and S2B).
Subsequently, we performed chromatin immunopre-
cipitation (ChIP) in the presence and absence of androgens 
using an antibody against MYC. Strikingly, MYC bound 
significantly (p < 0.05) to the TSS of all genes in the  purine 
biosynthesis pathway with the exception of ADSSL1, 
thereby suggesting a direct and global regulation of purine 
biosynthesis in PCa cell lines (Figure 1F). In conditions of 
androgen treatment, MYC levels were significantly reduced 
in the VCaP cell line and MYC enrichment at the TSS was 
concomitantly lower.
Taking together both the expression and ChIP 
approaches, we defined direct MYC regulated genes as 
genes that both mirrored changes in MYC levels in both 
directions and exhibited MYC binding in their respective 
promoter. Thus, PPAT, GART, PFAS, PAICS, ADSL and 
IMPDH2 are under the direct control of MYC in two 
metastatic PCa cell lines, as illustrated in Figure 2A.
PAICS and IMPDH2 are overexpressed in two 
independent patient cohorts
Next we used recursive partitioning to determine 
whether at any expression threshold any of the genes 
in this pathway were predictive of post-operative BCR 
in the Taylor dataset. Two genes within the pathway, 
IMPDH2 (p-value = 0.036) and PFAS (p-value = 0.038), 
were significantly associated with time to BCR when 
overexpressed (Figure S3A). Based on overexpression 
in the Oncomine database and prognostic significance 
(Figure S1D and Figure S3A), we then went on to 
validate the expression of PAICS and IMPDH2 in two 
independent clinical cohorts using real-time PCR and 
immunohistochemistry (IHC).
First, we determined the relative mRNA expression 
levels of MYC and the two putative targets PAICS and 
IMPDH2 in a well-established patient cohort [23]. 
The expression of MYC was elevated in both PCa and 
CRPC patients (p < 0.05) with no significant difference 
between the two groups (Figure 2B). On the other hand, 
both PAICS and IMPDH2 RNA levels were significantly 
increased in CRPC patients only (p < 0.01 and p < 0.001, 
respectively) with no significant difference between 
benign hyperplasia (BPH) and PCa patients or PCa and 
CRPC (Figure 2B). The expression of MYC in CRPC 
samples was also tightly correlated with the expression 
of IMPDH2 (R2 = 0.504) but not with PAICS (R2 = 0.17) 
(Figure S3B).
Second, we examined the protein expression 
levels of PAICS and IMPDH2 using tissue microarrays 
(TMAs) in another patient cohort, previously used to 
assess a number of clinically relevant biomarkers, such 
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Figure 1: The expression of purine biosynthesis enzymes in prostate cancer cells is directly regulated by 
MYC. A. Illumina beadarray results. LNCaP MYC cells were hormone-deprived for 72 h prior to stimulation with 2 μg/ml Doxycycline 
or vehicle for the indicated time points to induce MYC-overexpression. Total RNA of three independent experiments was isolated and 
subjected to expression array analysis. Genes with significantly altered expression (q < 0.05) compared to vehicle treated cells are displayed 
using unsupervised hierarchical clustering (left). Functional annotation using KEGG pathway analysis of 266 genes defined as ‘upregulated 
by MYC-overexpression at both time points’ is shown (right). B. Expression data from a previously published study (Taylor et al.) was 
used to define candidate MYC-regulated genes. Only patients marked as ‘biochemical recurrence (BCR)’ or ‘metastases (METS)’ were 
included in the analysis. Similarity search using Pearson correlation (1% tolerance) was performed on MYC expression and displayed using 
unsupervised hierarchical clustering with genes on the Y-axis and patients on the X-axis (left). Functional annotation of the 264 MYC-
correlated genes using KEGG pathway analysis at 1% tolerance is shown (right) C. Real-time PCR results of MYC-overexpressing cells. 
LNCaP MYC cells were hormone-deprived for 72 h prior to stimulation with 2 μg/ml Doxycycline to induce MYC-overexpression. Total 
RNA was isolated, reverse transcribed and used for qRT-PCR. n = 3 (D-E) Cells were transfected with 50 nM of control or MYC siRNA 
for 72 h. D. Real-time PCR results of MYC-depleted cells. Total RNA was isolated, reverse transcribed and used for qRT-PCR. n = 3–4 
E. Western Blot results of MYC-depleted cells. Protein lysates were harvested, separated by SDS-PAGE and blotted for the indicated 
proteins. Protein levels were normalized to siCTRL and β-actin levels. Densitometry analysis of three biological replicates with SEM can 
be found in Figure S1H. F. ChIP-qPCR detection of promoter regions of purine biosynthesis genes in MYC ChIP samples. Cells were 
hormone-deprived for 72 h prior to stimulation with 1 nM R1881 or vehicle for 4 h. Subsequently, chromatin was crosslinked, sonicated 
and subjected to ChIP using an antibody against MYC or an unspecific IgG control. n = 3.
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as CAMKK2 or TAF1 [7, 28]. Examples of positive and 
negative controls for our staining can be found in the 
supplementary data (Figure S4). PAICS exhibited strong 
staining in less than 10% of the benign samples and in 
more than 45% of both PCa and CRPC patients, a highly 
significant increase (p < 0.0001 for both comparisons) 
(Figure 2C/D and S3C). Inversely, IMPDH2 showed 
high expression levels in 40% of benign samples and 
no significant increase in PCa patients. However, a 
significant increase (p < 0.05) could be observed in CRPC 
cases where more than 70% of the samples exhibited 
strong staining (Figure 2C/D and S3C). The TMA cohort 
also contained samples taken by repeat biopsy during 
treatment with neoadjuvant hormone therapy (NHT) 
over a 12 month period including pre-treatment samples. 
In contrast to androgen-regulated genes validated in 
this cohort, including CAMKK2 [7], neither PAICS 
nor IMPDH2 levels were significantly decreased by 
short (1–6 months) or prolonged (7–12 months) NHT 
(Figure 2C). Sustained high levels of expression make 
these enzymes interesting therapeutic targets and further 
support the androgen-independent regulation of their 
expression.
Inhibition of IMPDH2 impairs proliferation of 
prostate cancer cell lines and shows additive 
effects with established anti-androgens
Next, to determine whether PAICS or IMPDH2 are 
essential for PCa cell proliferation, we applied siRNA-
mediated knockdown and assessed the proliferation 
of LNCaP, VCaP and an derivative of LNCaP that has 
acquired resistance to androgen deprivation, LNCaP-abl 
[29] using a colourimetric-based assay (MTS). Whilst 
depleting these cells of PAICS had only a modest effect on 
proliferation, knockdown of IMPDH2 using two different 
siRNAs significantly (p < 0.05) reduced the number of 
viable cells in all three lines by about 15–20% (Figure 3A, 
knockdown efficacy was assessed in Figure S5A). We 
also included siRNA against IMPDH1, the other IMPDH 
isoform, and observed cell-line specific differences; 
LNCaP and LNCaP-abl were unaffected by IMPDH1 
knockdown whilst VCaP exhibited effects comparable 
to IMPDH2 knockdown (Figure 3A). Intriguingly, a 
selective and uncompetitive inhibitor for IMPDH1 and 
2, Mycophenolic acid (MPA) is a clinically approved 
immunosuppressant, commonly used to prevent organ 
transplant rejection [30]. MPA induced a dose-dependent 
inhibition of proliferation in all three lines (Figure 3B) 
and caused predominantly cytostatic effects as determined 
using a fluorescence-based assay to measure caspase 
cleavage in cultured cells over time (Figure S5C). For 
further experiments, we chose doses that reduced cell 
proliferation by about 20–30% (LNCaP 10 μM and 
VCaP 5 μM).
We have previously shown that the AR promotes 
glycolysis and anabolic metabolism [7]. Since purine 
biosynthesis appears to be a purely MYC-dependent 
pathway in androgen-responsive PCa cell lines without 
involvement of the AR, we hypothesized that combining 
either an inhibitor of androgen biosynthesis (Abiraterone) 
or a next-generation anti-androgen (Enzalutamide/
MDV3100) with either siRNA against IMPDH2 or 
MPA would increase response to these drugs. Drug 
concentrations of Abiraterone and MDV3100 were 
chosen which gave maximally 20% reductions in viability 
when administered as single agents (Abiraterone: 1 μM 
for LNCaP and VCaP, MDV3100: 1 μM for LNCaP and 
100 nM for VCaP). LNCaP-abl did not show a significant 
response to either Abiraterone or MDV3100 and thus 
were excluded from these experiments (data not shown). 
As hypothesized, combining siRNA against IMPDH2 with 
Abiraterone or MDV3100 had additive effects in both 
lines (Figure 3C). IMPDH2 knockdown alone induced a 
~40% reduction in viability, either drug induced a ~20% 
reduction in viability, and combined we observed a ~60% 
reduction in viability (Figure 3C). We also performed these 
experiments using siRNA against siIMPDH1 (Figure S5B). 
As expected from the siRNA results alone (Figure 3A), 
we observed additive effects in VCaP but not LNCaP 
cells, suggesting that the expression and activity spectra 
of the IMPDH isoforms differ in both lines (Figure S5B). 
Combining MPA with Abiraterone or MDV3100 showed 
similar additive results (Figure 3D) and in all combinations 
the drugs were primarily cytostatic (Figure S5C). We also 
obtained a MDV3100-resistant LNCaP clone [31], and 
found that despite resistance to MDV3100 (20 μM), the 
clone remains equally responsive to MPA as the parental 
derivative (Figure 3E). Furthermore, we tested whether 
inhibition of IMPDH2 was dependent on MYC. Thus, we 
applied siRNA-mediated knockdown of MYC prior to 
treatment with two different doses of MPA (Figure 3F). 
We found that in all three lines, the efficacy of MPA was 
significantly (p < 0.05) reduced in a MYC-knockdown 
background (Figure 3F).
MPA depletes cellular GTP levels and leads 
to nucleolar stress, p53 stabilization and 
downregulation of MYC
MPA was initially developed and clinically 
approved as an immunosuppressant to enhance 
transplant engraftment based on the increased nucleotide 
demands of expanding immune cell populations [30]. 
To confirm the selective effects of the drug on guanine 
nucleotide synthesis in LNCaP and VCaP cells, we 
analyzed the cellular nucleotide pools using high-
pressure liquid chromatography (HPLC) after short (6 h) 
or prolonged (24 h) MPA treatment. We were able to 
confirm a significant reduction of cellular GTP pools to 
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Figure 3: Inhibition of IMPDH2 impairs the proliferation of prostate cancer cells and shows additive effects with 
established anti-androgens. A. Cell viability results of siRNA treated cells. Cells were transfected with 25 nM (control 25 nM, 
IMPDH1 and IMPDH2 #1) or 50 nM (control 50 nM, PAICS, IMPDH2 #2 and MYC) for 72 h and cell viability relative to siCTRL 50 nM 
was determined using a MTS-based assay. n = 2–4 B. Cell viability results of MPA treated cells. Cells were allowed to attach for 48 h 
prior to treatment with indicated doses of MPA for 72 h. Cell viability relative to vehicle control was determined using a MTS-based assay. 
n = 2–4 C. Cell viability results of siRNA and Abiraterone/MDV3100 treated cells. Cells were transfected with 25 nM IMPDH2 #1, 50 nM 
IMPDH2 #2 siRNA or equal amounts of siCTRL for 48 h. Following treatment with the indicated drugs for another 72 h, viability relative 
to DMSO and siCTRL was assessed using a MTS-based assay. Doses for LNCaP were 1 μM Abiraterone and 1 μM MDV3100, and for 
VCaP 1 μM Abiraterone and 100 nM MDV3100 n = 1–4 D. Cell viability results of MPA and Abiraterone/MDV3100 treated cells. Cells 
were allowed to attach for 48 h prior to treatment with indicated drug combinations for 72 h. Cell viability relative to vehicle control was 
determined using a MTS-based assay. Doses for LNCaP were 10 μM MPA, 1 μM Abiraterone and 1 μM MDV3100, and for VCaP 5 μM 
MPA, 1 μM Abiraterone and 100 nM MDV3100 n = 3–4 E. Cell viability results of MPA treated parental and MDV3100-resistant LNCaP. 
Cells were allowed to attach for 48 h prior to treatment with the indicated doses of MPA for 72 h. Cell viability relative to vehicle control 
was determined using a MTS-based assay. n = 4 F. Cell viability results of siRNA and MPA treated cells. Cells were transfected with 
50 nM MYC or control siRNA for 48 h. Following treatment with the indicated doses of MPA (LNCaP 5 and 10 μM, VCaP 5 and 10 μM 
and LNCaP abl 1 and 10 μM) for another 72 h, viability was assessed using a MTS-based assay and normalized to the respective DMSO 
control. n = 3.
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about 15–20% of the original levels, as expected from 
inhibiting an enzyme responsible for converting IMP to 
XMP, which in turn is converted to GMP (Figure 4A). 
Importantly, the levels of other nucleotide triphosphates 
remained largely unchanged. Furthermore, the cytostatic 
effects of MPA could be abolished in LNCaP and partially 
in VCaP cells by supplementing the cells with guanosine 
(100 μM), the final product of the guanine nucleotide 
biosynthetic pathway (Figure 4B).
GTP depletion has previously been shown to disrupt 
pre-rRNA synthesis and induce nucleolar stress [32]. In 
particular, the nucleolar protein guanine nucleotide-
binding protein-like 3 (GNL3) has been reported to 
be destabilized when GTP biosynthesis is inhibited 
[33, 34]. Western blots of protein extracts harvested 
from MPA-treated LNCaP and VCaP cells on a time 
course up to 24 hours confirmed this stress response in 
both lines (reduction to approximately 10–20% after 24 h 
treatment), which could be rescued by adding guanosine 
(Figure 4C). Nucleolar stress has been shown to stabilize 
p53 and trigger cell cycle arrest [35–37]. We therefore 
blotted for p53 and found that MPA treatment led to a 
significant increase in p53 levels in the wild-type line 
LNCaP (approximately 10 to 20-fold), whilst failing to 
do so in the p53-mutant VCaP line (Figure 4C). This was 
corroborated by an upregulation of the direct p53 target 
p21 (CDKN1A) by about 5 to 6-fold, both in protein and 
mRNA levels (Figure 4C and 4D, respectively). We also 
observed a previously reported compensatory increase in 
IMPDH2 mRNA and protein (approximately 4-fold and 2 
to 3-fold, respectively), albeit without a recovery in GTP 
levels (Figure 4C, 4D and 4A). In addition, MPA treatment 
led to a feedback reduction in MYC expression in both the 
protein (30–60% reduction at 24 h) and transcript levels 
(maximum 70% reduction at 6 h) (Figure 4C and 4D, 
respectively).
This implied an inhibition of either MYC 
transcription or mRNA stability/processing. A number 
of microRNAs have recently been reported to repress 
MYC expression and function as tumour suppressors, 
including the let7 and miR-34 clusters as well as miR-145 
[38–40]. Some of these are also known to be p53 targets 
and we selected a subset with both characteristics to test 
whether MPA treatment also increased the expression 
of these miRNAs. Confirming our hypothesis, 24 h 
MPA treatment of the p53 wild-type cell line LNCaP 
significantly increased miR-34b expression approximately 
2.5-fold and miR-145 expression approximately 2-fold 
while at the same time suppressing miR-34c by about 
50% (Figure 4E). In contrast, the expression of miR-34a 
was not significantly altered. These miRNAs could not 
be detected in VCaP cells (data not shown), suggesting 
that other mechanisms might contribute to the observed 
downregulation of MYC in this line.
To assess the role of p53 in the wild type line LNCaP, 
we knocked down its expression using siRNA and treated 
the cells with MPA (Figure 4F/G). p53 knockout partially 
restored the proliferation of LNCaP cells (by approximately 
10–15%), suggesting that p53 and putatively p21 are at 
least partially responsible for the observed reduction in 
proliferation (Figure 4F). We also treated the cells with 
MPA on an extended time course (6–72 h) and blotted 
for IMPDH2, GNL3, p53, p21 and MYC (Figure 4G). 
Interestingly, no major changes in the protein levels of 
GNL3 and MYC could be observed, which suggested that 
the effects of MPA on these proteins were independent of 
p53. This was further corroborated by the observation that 
hydroxyurea, a known ribonucleotide reductase inhibitor 
and activator of p53, had no effect on GNL3 and only a 
modest effect on MYC levels (Figure S5D).
In conclusion, we find that IMPDH2 expression 
is elevated in PCa and that inhibition has the feedback 
capacity to reduce the expression of MYC and to increase 
the sensitivity of PCa cells to anti-androgens and androgen 
synthesis inhibitors.
DISCUSSION
The oncogenic transcription factor MYC is a 
complex transcription factor and even after decades 
of research, its exact functions in PCa initiation 
and progression remain unclear. Previous unbiased 
approaches in other cell types, such as embryonic stem 
cells and human B-cells, revealed MYC to be the driver 
of anabolic metabolism and biomass accumulation 
through the regulation of amino acid metabolism, 
ribosome biogenesis and purine metabolism [14, 15, 41]. 
In PCa, the amplification of the MYC locus on 8q24 
is predictive of poor prognosis [42, 43]. Additional 
increased MYC expression predicts poor outcome and 
overexpression of MYC in PCa cell lines and mouse 
models promotes castrate-resistant and mTOR inhibitor-
resistant growth, and alters the expression levels of other 
hormone-receptors, such as estrogen receptor alpha (ERa) 
[10, 44–46]. However, so far identification of MYC-
dependent genes mediating these effects in PCa has been 
limited to a study reconfirming the contribution of MYC 
to the expression of ribosomal and nucleolar genes [17]. 
For the first time, our work combined an in vitro approach 
using an inducible MYC overexpression system in LNCaP 
cells and in silico analysis of a clinical dataset in order to 
define clinically relevant MYC transcriptional networks 
in PCa (Figure 1). We reconfirmed the MYC-dependent 
expression of nucleolar and ribosomal genes, but 
progressed beyond this to identify a metabolic pathway, 
which alters the response to AR-targeted therapies, the 
de novo purine biosynthesis pathway. This pathway, 
alongside ribosome and nucleolar biogenesis, can be 
regarded as supporting processes to sustain elevated rates 
of transcription, replication and cell division in transformed 
cells. Interestingly, the genes in the purine biosynthesis 
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Figure 4: Inhibition of IMPDH2 leads to nucleolar instability, p53 activation and upregulation of MYC-targeting 
miRs. A. HPLC results of cellular nucleoside triphosphate levels. LNCaP and VCaP cells were treated with 10 μM MPA for the indicated 
time points, lysed and subjected to HPLC to detect cellular levels of presented nucleoside triphosphates (NTP). Values were normalized 
to DMSO treated cells and protein content. n = 3 B. Cell viability results of MPA treated cells. Cells were allowed to attach for 48 h prior 
to treatment with indicated doses of MPA and guanosine (100 μM) for 72 h. Cell viability relative to vehicle control was determined 
using a MTS-based assay. n = 3 C. Western blot results of MPA treated PCa cells. LNCaP and VCaP cells were treated with 10 μM MPA 
and 100 μM guanosine (G) for the indicated time points. Protein extracts were harvested and subjected to Western blot analysis using the 
indicated primary antibodies. Protein levels were normalized to DMSO controls and GAPDH levels. D. Real-time PCR results. LNCaP 
cells were treated with 10 μM MPA for the indicated time points. Total RNA was isolated, reverse transcribed and used for qRT-PCR. n = 3 
E. miRNA detection using real-time PCR of MPA treated LNCaP. Cells were treated with 10 μM MPA for the indicated time points prior to 
total RNA isolation using Trizol reagent and miR-detection using TaqMan assays. n = 2 F. Cell viability results of siRNA and MPA treated 
cells. Cells were transfected with 50 nM control or p53 siRNA for 48 h. Following treatment with the indicated drugs for another 72 h, 
viability was assessed using a MTS-based assay. n = 3 G. Western Blot results of siRNA and MPA treated LNCaP. Cells were transfected 
with 50 nM control or p53 siRNA for 48 h and then treated with 10 μM MPA and 100 μM guanosine (G) for the indicated time points. 
Protein lysates were harvested, separated by SDS-PAGE and blotted for the indicated proteins.
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pathway are not androgen regulated, but rather 
MYC dependent (Figure S1F/G and Figure 1C–1F), 
which is intriguing in the light of a recent report 
highlighting AR as a driver of several anabolic processes, 
including the pentose phosphate shunt pathway, which 
feeds metabolites into the purine biosynthesis pathway [7]. 
In this study, however, the expression levels of the 
enzymes themselves were not reported to be AR regulated.
We then went on to address the question whether 
enzymes within the pathway might serve as cancer 
biomarkers. Neither PAICS nor IMPDH2 have been 
evaluated as potential biomarkers in PCa. However, 
IMPDH2 has been tested as a potential biomarker using 
IHC in colorectal cancer and appears to be a promising 
target for both detection and treatment [47]. Our findings 
suggest potential for IMPDH2 as a biomarker in PCa 
since a significant increase in mRNA levels could only 
be observed in CRPC and not in BPH or localized PCa 
samples (Figure 2B). Furthermore, CRPC cases exhibited 
a significant increase in IHC staining when compared to 
BPH samples (Figure 2C).
On the other hand, PAICS has not been assessed as 
a potential biomarker in any cancer previously. Similar to 
IMPDH2, PAICS mRNA levels were only significantly 
increased in CRPC but not in PCa (Figure 2B). Strong IHC 
staining for PAICS, however, occurred almost exclusively 
in PCa or CRPC cases and almost 50% of the BPH cases 
exhibited only weak staining (Figure 2C). Recent work 
highlights the metabolite SAICAR (the product of the 
reaction catalyzed by PAICS) as a regulator of pyruvate 
kinase and describes its growth-promotion functions in 
glucose-limited conditions - conditions that often occur 
in the nutrient-limited environment of solid tumours [48]. 
PAICS appears to be regulated by MYC in other cancer 
types, which further emphasizes the important roles this 
enzyme may play in cancer [49]. Our study is the first to 
assess it as a potential biomarker in any cancer and we 
find that its expression is significantly increased at the 
transcript and protein level in two cohorts, meriting future 
studies to assess it as a surrogate marker for the pathway 
as a whole.
Next, we determined whether IMPDH2 or PAICS 
constitute important metabolic enzymes for maintaining 
the proliferation of androgen-responsive and -independent 
PCa cell lines (Figure 3). Whilst IMPDH2 knockdown 
using two different siRNAs significantly reduced cell 
viability in three different cell lines, PAICS knockdown 
had no effect (Figure 3A). This, however, may relate to 
the differing contributions of these enzymes to metabolite 
production as PAICS is a multifunctional enzyme in the 
de novo purine biosynthesis pathway but not reported 
to be rate limiting [50]. By contrast, IMPDH2 is a rate-
limiting enzyme for guanine nucleotide biosynthesis and 
we hypothesized that the growth reduction observed by 
IMPDH2 knockdown might reflect depletion of guanine 
nucleotides. Inhibitors of IMPDH1/2 have been available 
for decades, initially to limit immune responses to 
transplant surgery, with the best characterized example 
being Mycophenolic acid (MPA) [30]. Treatment with this 
drug led to > 80% reduction in GTP levels (Figure 4A) 
and to significant reduction in cell viability, which 
could be rescued completely in LNCaP and partially in 
VCaP cells by adding guanosine, the final product of the 
guanine nucleotide biosynthetic pathway (Figure 3B and 
Figure 4B). In contrast to LNCaP cells, VCaP cells are 
sensitive to siRNA-mediated knockdown of IMPDH1, a 
second isoform of the IMPDH family (Figure 3A). MPA 
is known to target both isoforms and the difference in 
sensitivity to IMPDH1 knockdown may contribute to 
the inability of guanosine to rescue MPA-treated VCaP 
completely at equivalent concentrations to those, which 
effectively rescued LNCaP (Figure 4B).
Next, we combined an anti-androgen (MDV3100) 
and an androgen synthesis inhibitor (Abiraterone) with 
MPA or siRNA against IMPDH2 and observed an additive 
reduction in cell viability (Figure 3C and 3D), which 
further highlights the AR-independence of this pathway. 
We also observed an additive reduction in viability of 
IMPDH1 knockdown in combination with Abiraterone and 
MDV3100, albeit only in VCaP cells (Figure S5B). This 
suggests cell line specific differences in the expression 
and activity spectra of the IMPDH isoforms. Furthermore, 
a MDV3100 resistant LNCaP clone remained sensitive 
to MPA (Figure 3E). This is particularly intriguing as 
MDV3100-resistance has recently been observed in 
late-stage CRPC patients [51]. We also assessed the 
dependency of MPA inhibition on MYC expression 
and found that MYC knockdown significantly reduced 
the efficacy of MPA underscoring the tight relationship 
between MYC and the response to a drug targeting a 
MYC-dependent enzyme (Figure 3F).
Among other core cellular processes, GTP has 
previously been reported to be critical for regulating 
nucleolar stability and assembly, in part through binding 
by the nucleolar protein GNL3 [52]. It has been shown 
that GTP depletion triggers the degradation of GNL3 
and other nucleolar components, thereby leading to 
nucleolar stress [33]. We confirmed that MPA treatment 
induced these effects in PCa cells, as well as a previously 
reported feedback stabilization of the target enzyme, 
IMPDH2, due to the formation of a stable complex 
with MPA [53] (Figure 4C). Importantly, increased 
protein levels of IMPDH2 failed to restore GTP levels 
(Figure 4A). Although not explicitly tested for in this 
setting, it is conceivable that MPA treatment induces 
widespread changes in cellular nucleotide metabolism. 
IMP, a substrate for IMPDH1/2, is also an important 
substrate for other enzymes, such as ADSSL1, which 
synthesizes AMP (Figure 2A). Consequently, IMP is 
at a branching point in the purine biosynthesis pathway 
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and the conversion of IMP to either GMP or AMP is 
energy-dependent. The energy source, however, is 
different for each product and reciprocal, i.e. ATP as an 
energy source drives GMP synthesis and conversely, 
GTP drives AMP production. Thus, the accumulation 
of excess ATP favours GMP production. Furthermore, 
the nucleotide salvage pathway can sustain IMP levels 
through the activity of the enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) [54]. Consequently, 
MPA treatment may induce compensatory effects, not 
sufficient to offset nucleolar stress where there is a 
strong guanine nucleotide dependency, but perhaps to 
upregulate other IMP converting enzymes (e.g. ADSSL1), 
as observed in response to MYC knockdown (Figure 1D) 
or upregulation of enzymes of the purine salvage pathway 
(e.g. HGPRT) to salvage the scarce guanosine [54].
Nucleolar stress has pleiotropic tumour suppressive 
effects depending on cell type and genetic background. 
One major effect can be on p53 stability and activity, 
with stress induction leading to the stabilization of p53 by 
inhibiting the MDM2-p53 complex [32]. We found that 
MPA treatment stabilized p53 in PCa cells in a wild-type 
setting (LNCaP) whilst failing to have a significant impact 
on p53 levels in a mutant line (VCaP) (Figure 4C). This 
was also observed for a well-characterized target gene of 
p53, the cyclin-dependent kinase inhibitor p21 (CDKN1A) 
(Figure 4C and 4D). Interestingly, in both cell lines MYC 
levels were significantly reduced upon MPA treatment at 
both the transcript and protein level (Figure 4C and 4D). 
It has previously been shown that MYC levels in PCa 
cells can be reduced through the activity of the miR-34 
cluster and miR-145 [39, 40]. Since these miRs are also 
p53-regulated [55, 56], we tested whether they were 
overexpressed in response to MPA treatment. Two miRs, 
miR-34b and miR-145, were increased in expression in the 
LNCaP cell line (Figure 4E).
In order to assess the contribution of p53 to these 
changes, we knocked down its expression using siRNA 
in the LNCaP cell line. Knockdown of p53 rendered the 
LNCaP cell line less sensitive to the cytostatic effects of 
MPA (Figure 4F). Strikingly, this was not due to changes 
in GNL3 or MYC protein levels, as assessed by western 
blotting on an extended timecourse from 6–72 h treatment 
(Figure 4G). This suggests that while p53 appears to be, 
at least partially, responsible for the cytostatic effects of 
MPA in LNCaP, nucleolar stress and downregulation of 
MYC occur independently of p53. This is in line with our 
observations in the p53-mutant cell line VCaP where both 
GNL3 and MYC are downregulated in the absence of a 
significant increase in p53 or p21 (Figure 4C). Conversely, 
hydroxyurea, a known ribonucleotide reductase 
inhibitor and activator of p53, had no effect on GNL3 
and only a modest effect on MYC levels (Figure S5D), 
suggesting the induction of nucleolar stress is specific 
to MPA.
Strikingly, several other mechanisms of MYC-
suppression have been discovered in various cell types and 
these might also contribute to the observed downregulation 
of MYC in our experiments. For example, the ribosomal 
proteins RPL5 and RPL11, which are responsible for the 
inhibition of the MDM2-p53 complex and concomitant 
stabilization of p53, have also been shown to suppress 
MYC directly both on transcript and protein level in 
lung cancer cells [57, 58]. This might be one possible 
explanation for why VCaP cells, which harbour a p53 
mutation, also respond to MPA. However, the exact 
functional impact of the p53 mutation in VCaP has not 
been explored yet.
In this paper, we were able to show in the LNCaP 
cell line strong associations between MPA treatment, p53 
stabilisation and the increased expression of known p53-
driven oncosuppressive microRNAs, miR-34b and miR-
145, which have previously been reported to target MYC. 
Therapeutically, these miRs are particularly interesting 
in the light of recently published novel cancer therapy 
approaches, which involve the restitution of tumour 
suppressive miRs, including miR-145, through viral or 
nanoparticle delivery of expression vectors [59, 60]. The 
challenge is to translate these novel therapeutics into 
patients. In contrast to this approach, MPA is already a 
commonly prescribed immunosuppressant and well-
characterised in a clinical setting. Current treatment 
options for CRPC include anti-mitotic chemotherapeutics 
(Docetaxel and Cabazitaxel), AR-targeting agents 
(Abiraterone and MDV3100) and notably the 
immunosuppressant Prednisone. A very recent trial of 
prednisone in combination with Abiraterone showed a 
significant survival benefit for the combination in men 
with chemotherapy-naive castration-resistant prostate 
cancer [61]. Our study is the first to suggest a second, 
clinically approved immunosuppressant as a putative 
treatment option for late-stage CRPC. However, further 
validation in preclinical models of PCa will be needed to 
assess the suitability of MPA treatment in patients [62].
In conclusion, our study highlights the potential to 
exploit purine biosynthesis and specifically the activity 
of IMPDH2 to diminish the expression and activity of 
MYC and enhance response to clinically approved PCa 
drugs. Whilst MPA has long been clinically approved, 
inhibitors with greater selectivity for IMPDH2 are under 
development [63] and it remains to be seen whether these 
drugs will provide greater efficacy, particularly in PCa. 
New IMPDH inhibitors will certainly provide greater 
opportunities for combination trials in the near future and 
the potential to do so is also enhanced by the existence 
of assays to measure GTP levels in peripheral blood 
mononuclear cells and the levels of IMPDH2 in serum 
[64–66]. This might potentially be relevant as surrogate 
response and treatment stratification markers but needs 
to be further assessed in PCa cohorts. Finally, as the 
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relationship between transcription and metabolism in 
PCa is more extensively explored, so additional clinically 
relevant feedback loops will be uncovered and provide 
new targets for intervention.
MATERIALS AND METHODS
A more detailed version of the materials and 
methods used can be found in the supplemental material.
Immunohistochemistry
This study was done on a total of 194 PCa 
specimens obtained from Vancouver Prostate Centre 
Tissue Bank. The H&E slides were reviewed and 
the desired areas were marked on them and their 
correspondent paraffin blocks. 3 TMAs were manually 
constructed (Beecher Instruments, MD, USA) by punching 
duplicate cores of 1 mm for each sample. All the specimen 
were from radical prostatectomy except 12 CRPC samples 
that obtained from transurethral resection of prostate 
(TURP).
Immunohistochemical staining was conducted 
by Ventana autostainer model Discover XTTM (Ventana 
Medical System, Tuscan, Arizona) with enzyme labeled 
biotin streptavidin system and solvent resistant Red Map 
kit by using 1:600 of PAICS rabbit polyclonal antibody 
(Sigma, HPA035895) and 1:2,000 concentrations 
of IMPDH2 rabbit monoclonal antibody (Epitomics, 
5814–1), respectively.
The antibodies were validated in the following 
manner.
PAICS: Using Protein Atlas as our reference, we 
stained Ovarian Cancer and Normal Liver as our positive 
controls. Prostate Stromal cells were our negative controls.
http://www.proteinatlas.org/ENSG00000128050-
PAICS/cancer
IMPDH2: Using Protein Atlas as our reference, we 
stained Ovarian Cancer and Benign atrophic Testis as our 
positive control. Prostate Stromal cells were our negative 
controls.
http://www.proteinatlas.org/ENSG00000178035-
IMPDH2/cancer
Representative images of positive and negative 
controls can be found in Figure S4.
Values on a four-point scale were assigned to 
each immunostain. Descriptively, 0 represents no 
staining by any tumor cells, 1 represents a faint or 
focal, questionably present stain, 2 represents a stain of 
convincing intensity in a minority of cells and 3 a stain of 
convincing intensity in a majority of cells.
Quantitative real-time PCR (qRT-PCR)
Samples were run in duplicates and transcript levels 
were normalized to vehicle controls and the expression 
levels of β-actin using the 2^ddCt method. A list of 
primers used for the real-time PCR experiments can be 
found in Figure S2B.
Real-time PCR on clinical samples was performed 
as previously described [23]. For a detailed list of primer 
pairs used, see Figure S2B.
The quantification of miRNA levels was performed 
according to the TaqMan Micro-RNA Assays protocol 
(Applied Biosystems). Briefly, RNA was reverse 
transcribed with miR–34a, –34b, –34c and –145 
specific primers (TaqMan Assay nos. 000426, 002102, 
000428, and 002278 respectively) and samples were 
run in quadruplicates. Transcript levels were normalized 
to vehicle controls and the expression levels of the 
geometric mean of RNU48 and RNU66 using the 2^ddCt 
method.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the Human MYC 
ExactaChIP Chromatin IP kit (R&D, ECP3696) and 
1% of total chromatin was taken as input control prior 
to overnight incubation with the antibody. ChIP-qPCR 
was perfomed using the SYBR green master mix and 
same amplification conditions as for qRT-PCR. Results 
are being displayed as ‘% of input’ using the formula 
2^(ct(Input)-ct(antibody)). For a detailed list of primer 
pairs used, see Figure S2B.
siRNA transfection
The following siRNAs were used: ON-TARGETplus 
Non-Targeting Pool (Thermo Scientific, D-001810–10), 
ON-TARGETplus Human MYC SMARTpool (Thermo 
Scientific, L-003282–02), ON-TARGETplus Human 
PAICS SMARTpool (Thermo Scientific, L-003980–00), 
siIMPDH2 #1: siIMPDH2 Silencer Select (Ambion, 
106309), siIMPDH2 #2: ON-TARGETplus Human 
IMPDH2 SMARTpool (Thermo Scientific, L-004330–
00) and Human p53 SMARTpool (Thermo Scientific, 
L-003329–00).
Western blot analysis
Primary antibodies used were PAICS (Sigma, 
HPA035895), IMPDH2 (Sigma, HPA001400), MYC 
(Abcam, ab32072), AR (Santa Cruz, sc-816), p53 
(Santa Cruz, sc-126), GNL3 (R&D, AF1638), KLK3 
(Dako, D0487), b-actin-HRP (Cell Signaling, 5125) 
and GAPDH (Cell Signaling, 2118). Secondary 
HRP-conjugated anti-rabbit and anti-mouse were 
purchased from Dako (P0448 and P0447, respectively). 
Densitometry analysis was performed using the freely 
available software ImageJ and protein levels normalized 
to vehicle controls and the indicated loading control 
(b-actin or GAPDH).
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Statistics
Unless stated otherwise, mean values with standard 
error of the mean (SEM) are displayed and significance 
was confirmed using paired two-tailed Student’s t-test. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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